{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-036150","form_type":"8-K","ticker":null,"cik":"0001971543","company_name":"Mural Oncology plc","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.396433+00:00","generated_at":"2026-06-04T08:09:30.036559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mural Oncology Q4 net loss $59.5M, cash $270.9M; nemvaleukin trials on track for 1H 2025 readouts","bullets":["Net loss of $59.5M for Q4 2023 includes $15.2M non-cash share-based compensation, mostly one-time spin-out charges.","Cash and equivalents $270.9M; cash runway projected into Q4 2025.","Phase 2 ARTISTRY-6 mucosal melanoma cohort (potentially registrational) top-line data expected 1H 2025.","New recommended phase 2 dose for LFIV dosing (30 µg/kg) to be evaluated in ARTISTRY-6 cohort 3.","Company intends to nominate development candidates for engineered IL-18 and IL-12 therapies in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-036150","json":"https://secwatch.observer/filing/0000950170-24-036150.json","markdown":"https://secwatch.observer/filing/0000950170-24-036150.md","text":"https://secwatch.observer/filing/0000950170-24-036150.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/0000950170-24-036150-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/mura-20240326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:09:30.036559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7d125176f04e450c601e2e2503152fa1184cefe","claim":"Mural Oncology plc reported the fourth quarter ended December 31, 2023 results: net income Net loss was $59.5 million for the fourth quarter of 2023.. Guidance reaffirmed.","evidence_excerpt":"Net loss was $59.5 million for the fourth quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971543/000095017024036150/0000950170-24-036150-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss was $59.5 million for the fourth quarter of 2023."},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}